In this sense, the authors were interested in exploring the association of the BCL2/miR‐497 expression profile with the clinic‐pathological characteristics and outcomes of CRC patients to help their prognostic stratification and future individualized therapeutic management. The gene discussed is BCL2; the disease is colorectal carcinoma.